Industry executives should think back to an earlier precedent: the move in cancer trials pushed by Genentech more than a decade ago to make mid-stage trials mirror approval studies, with control groups and patients who are randomly assigned either to get the drug or not.
Zimbabwe's cash-starved banks, and a central bank that has lost control of its currency, mirror challenges in other countries, including Greece, Malawi and Swaziland.